Oxidative stress and androgen receptor expression in castration-resistant prostate cancer

masaki shiota, Akira Yokomizo, Yasuhiro Tada, Junichi Inokuchi, Seiji Naito

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

There are few successful therapies for castration-resistant prostate cancer (CRPC). Recently, CRPC has been thought to result from augmentation of the androgen/androgen receptor (AR)-signaling pathway, with AR overexpression having been observed in most cases. In a previous study, we found that Twistl, a member of the basic helix-loop-helix transcription factors, regulated AR expression via binding to E-boxes within the AR promoter region. Twistl. which is known to be a stress-inducible factor, as well as AR, was upregulated in response to hydrogen peroxide. Furthermore, castration-resistant LNCaP derivatives and hydrogen peroxide-resistant LNCaP derivatives expressed high levels of both Twistl and AR, and they exhibited a castration-resistant phenotype, which was reversed by AR knockdown. Blockade of androgen/AR signaling by androgen deprivation and AR knockdown increased intracellular reactive oxygen species. Silencing of Twistl suppressed the cell growth of the LNCaP cells as well as the castration-resistant LNCaP derivatives by inducing cell-cycle arrest at the Gl phase and cellular apoptosis. These findings indicate that oxidative stress induced by castration may promote AR overexpression through Twistl overexpression, which could result in a gain of castration resistance. Modulation of castration-induced oxidative stress or Twistl/AR signaling may be a promising strategy for developing novel therapeutics in prostate cancer, even in cases of CRPC. Further intensive research in this field is essential in order to improve the outcome of therapy for advanced prostate cancer.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
JournalNishinihon Journal of Urology
Volume72
Issue number3
Publication statusPublished - Mar 2010

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Oxidative Stress
Androgens
Hydrogen Peroxide
Basic Helix-Loop-Helix Transcription Factors
Cell Cycle Checkpoints
Genetic Promoter Regions
Reactive Oxygen Species
Therapeutics
Apoptosis
Phenotype

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Oxidative stress and androgen receptor expression in castration-resistant prostate cancer. / shiota, masaki; Yokomizo, Akira; Tada, Yasuhiro; Inokuchi, Junichi; Naito, Seiji.

In: Nishinihon Journal of Urology, Vol. 72, No. 3, 03.2010, p. 97-102.

Research output: Contribution to journalArticle

@article{2a728b50bc6445eca6aab3d62ec45ebd,
title = "Oxidative stress and androgen receptor expression in castration-resistant prostate cancer",
abstract = "There are few successful therapies for castration-resistant prostate cancer (CRPC). Recently, CRPC has been thought to result from augmentation of the androgen/androgen receptor (AR)-signaling pathway, with AR overexpression having been observed in most cases. In a previous study, we found that Twistl, a member of the basic helix-loop-helix transcription factors, regulated AR expression via binding to E-boxes within the AR promoter region. Twistl. which is known to be a stress-inducible factor, as well as AR, was upregulated in response to hydrogen peroxide. Furthermore, castration-resistant LNCaP derivatives and hydrogen peroxide-resistant LNCaP derivatives expressed high levels of both Twistl and AR, and they exhibited a castration-resistant phenotype, which was reversed by AR knockdown. Blockade of androgen/AR signaling by androgen deprivation and AR knockdown increased intracellular reactive oxygen species. Silencing of Twistl suppressed the cell growth of the LNCaP cells as well as the castration-resistant LNCaP derivatives by inducing cell-cycle arrest at the Gl phase and cellular apoptosis. These findings indicate that oxidative stress induced by castration may promote AR overexpression through Twistl overexpression, which could result in a gain of castration resistance. Modulation of castration-induced oxidative stress or Twistl/AR signaling may be a promising strategy for developing novel therapeutics in prostate cancer, even in cases of CRPC. Further intensive research in this field is essential in order to improve the outcome of therapy for advanced prostate cancer.",
author = "masaki shiota and Akira Yokomizo and Yasuhiro Tada and Junichi Inokuchi and Seiji Naito",
year = "2010",
month = "3",
language = "English",
volume = "72",
pages = "97--102",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "3",

}

TY - JOUR

T1 - Oxidative stress and androgen receptor expression in castration-resistant prostate cancer

AU - shiota, masaki

AU - Yokomizo, Akira

AU - Tada, Yasuhiro

AU - Inokuchi, Junichi

AU - Naito, Seiji

PY - 2010/3

Y1 - 2010/3

N2 - There are few successful therapies for castration-resistant prostate cancer (CRPC). Recently, CRPC has been thought to result from augmentation of the androgen/androgen receptor (AR)-signaling pathway, with AR overexpression having been observed in most cases. In a previous study, we found that Twistl, a member of the basic helix-loop-helix transcription factors, regulated AR expression via binding to E-boxes within the AR promoter region. Twistl. which is known to be a stress-inducible factor, as well as AR, was upregulated in response to hydrogen peroxide. Furthermore, castration-resistant LNCaP derivatives and hydrogen peroxide-resistant LNCaP derivatives expressed high levels of both Twistl and AR, and they exhibited a castration-resistant phenotype, which was reversed by AR knockdown. Blockade of androgen/AR signaling by androgen deprivation and AR knockdown increased intracellular reactive oxygen species. Silencing of Twistl suppressed the cell growth of the LNCaP cells as well as the castration-resistant LNCaP derivatives by inducing cell-cycle arrest at the Gl phase and cellular apoptosis. These findings indicate that oxidative stress induced by castration may promote AR overexpression through Twistl overexpression, which could result in a gain of castration resistance. Modulation of castration-induced oxidative stress or Twistl/AR signaling may be a promising strategy for developing novel therapeutics in prostate cancer, even in cases of CRPC. Further intensive research in this field is essential in order to improve the outcome of therapy for advanced prostate cancer.

AB - There are few successful therapies for castration-resistant prostate cancer (CRPC). Recently, CRPC has been thought to result from augmentation of the androgen/androgen receptor (AR)-signaling pathway, with AR overexpression having been observed in most cases. In a previous study, we found that Twistl, a member of the basic helix-loop-helix transcription factors, regulated AR expression via binding to E-boxes within the AR promoter region. Twistl. which is known to be a stress-inducible factor, as well as AR, was upregulated in response to hydrogen peroxide. Furthermore, castration-resistant LNCaP derivatives and hydrogen peroxide-resistant LNCaP derivatives expressed high levels of both Twistl and AR, and they exhibited a castration-resistant phenotype, which was reversed by AR knockdown. Blockade of androgen/AR signaling by androgen deprivation and AR knockdown increased intracellular reactive oxygen species. Silencing of Twistl suppressed the cell growth of the LNCaP cells as well as the castration-resistant LNCaP derivatives by inducing cell-cycle arrest at the Gl phase and cellular apoptosis. These findings indicate that oxidative stress induced by castration may promote AR overexpression through Twistl overexpression, which could result in a gain of castration resistance. Modulation of castration-induced oxidative stress or Twistl/AR signaling may be a promising strategy for developing novel therapeutics in prostate cancer, even in cases of CRPC. Further intensive research in this field is essential in order to improve the outcome of therapy for advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=77951168498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951168498&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 97

EP - 102

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 3

ER -